Sonnet BioTherapeutics (SONN) Institutional Ownership → The Weight Loss Pill That Could Disrupt a $32 Billion Industry (From Behind the Markets) (Ad) Free SONN Stock Alerts Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for Sonnet BioTherapeutics (NASDAQ:SONN)CurrentInstitutional OwnershipPercentage9.45%Number ofInstitutional Buyers(last 12 months)2TotalInstitutional Inflows(last 12 months)$14.87MNumber ofInstitutional Sellers(last 12 months)0 Get SONN Insider Trade Alerts Want to know when executives and insiders are buying or selling Sonnet BioTherapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data SONN Institutional Buying and Selling by Quarter Ad InvestorPlace$21,000 in profits in six weeks? On Wednesday, May 8, the legendary Jonathan Rose is holding his first ever Masters in Trading Summit. Jonathan is one of the sharpest traders I’ve ever met. He made millions trading in the pits of the world’s largest exchanges.Click here for details. Sonnet BioTherapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails7/27/2023Virtu Financial LLC86,624$42K0.0%N/A0.315% 5/19/2023Anson Funds Management LP1,760,000$634K0.1%N/A6.405% 11/7/2022Virtu Financial LLC26,914$40K0.0%N/A0.622% 8/2/2022 Advisory Services Network LLC130,525$37K0.0%+158.3%0.215% 5/10/2022Campion Asset Management90,612$34K0.0%N/A0.150% 8/16/2021State Street Corp62,688$99K0.0%N/A0.253% 8/13/2021Vanguard Group Inc.701,634$1.11M0.0%+416.0%2.834% 5/19/2021Virtu Financial LLC65,106$146K0.0%N/A0.371% 5/18/2021Citadel Advisors LLC113,264$255K0.0%N/A0.534% 5/18/2021Jane Street Group LLC17,304$39K0.0%N/A0.099% 5/17/2021Price T Rowe Associates Inc. MD45,100$101K0.0%N/A0.257% 5/13/2021 Bank of New York Mellon Corp20,399$46K0.0%N/A0.116% 5/7/2021BlackRock Inc.255,761$575K0.0%+3.7%1.457% 3/26/2021Susquehanna International Group LLP15,434$34K0.0%N/A0.088% 2/9/2021 Advisory Services Network LLC24,581$55K0.0%+32.3%0.143% 2/5/2021BlackRock Inc.246,555$550K0.0%+2.5%1.435% 11/19/2020Schonfeld Strategic Advisors LLC12,200$31K0.0%N/A0.071% 11/19/2020IHT Wealth Management LLC10,000$26K0.0%N/A0.058% 11/17/2020Schonfeld Strategic Advisors LLC12,200$31K0.0%N/A0.089% (Data available from 1/1/2016 forward) SONN Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of SONN shares? During the previous two years, the following institutional investors and hedge funds held shares of Sonnet BioTherapeutics shares: Anson Funds Management LP ($634K), Virtu Financial LLC ($42K), and Advisory Services Network LLC ($37K), Campion Asset Management ($34K).Learn more on SONN's institutional investors. What percentage of Sonnet BioTherapeutics stock is owned by institutional investors? 9.45% of Sonnet BioTherapeutics stock is owned by institutional investors. Learn more on SONN's institutional investor holdings. Which institutional investors have been buying Sonnet BioTherapeutics stock? The following institutional investors have purchased Sonnet BioTherapeutics stock in the last 24 months: Anson Funds Management LP ($1.76M), Virtu Financial LLC ($113.54K), Campion Asset Management ($90.61K), and Advisory Services Network LLC ($80K). How much institutional buying is happening at Sonnet BioTherapeutics? Institutional investors have bought a total of 2,044,150 shares in the last 24 months. This purchase volume represents approximately $33.14M in transactions. Related Companies: Kazia Therapeutics Institutional Ownership Alzamend Neuro Institutional Ownership Kineta Institutional Ownership Cingulate Institutional Ownership Processa Pharmaceuticals Institutional Ownership NexImmune Institutional Ownership Petros Pharmaceuticals Institutional Ownership Exicure Institutional Ownership Bright Minds Biosciences Institutional Ownership Lixte Biotechnology Institutional Ownership This page (NASDAQ:SONN) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressCharles Payne Demystifies OptionsUnstoppable ProsperityThe AI Stock that’s Disrupting Every IndustryStockEarningsShocking: One AI startup's revenue could surge 4,735%Manward Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
